Harnessing a novel CRISPR nuclease for programmable counterselection in human cells
This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.
Projectdetails
Introduction
CRISPR technologies have revolutionized genome editing in medicine, agriculture, biotechnology, and life-sciences research with their ability to generate virtually any DNA edit at any genomic site in any organism. However, editing frequencies can be restrictively low, requiring extensive screening to identify cells harboring desired edits.
Problem Statement
What remains elusive is a way to greatly boost the frequency of editing. While characterizing CRISPR-Cas systems, bacterial defense systems, and the source of CRISPR technologies, we discovered a new mechanism that could kill unedited cells yet spare edited cells, regardless of the type of gene edit.
Proposed Solution
This versatile and sequence-specific approach can be described as programmable counter-selection, as undesired cells are targeted for removal, and those cells can be targeted in a programmable way. If proven, this capability could radically boost the effective editing frequencies by removing unedited cells regardless of the underlying edit, providing much-needed relief to the burden of screening imposed on diverse genome-editing applications.
Experimental Approach
Here, we propose to perform proof-of-concept experiments demonstrating this capability in human cells while exploring which editing applications would best benefit from this capability.
Background and Expertise
The associated tasks build on my extensive work at the interface of CRISPR biology and technologies and leverage my numerous academic and industrial contacts.
Future Goals
I ultimately aim to translate a novel biological insight from my group’s ERC Consolidator project into an innovative foundational technology, with a clear path toward its broad use in genome editing.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-4-2024 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Profile nucleases and Repurpose Off-Targets to Expand Gene EditingThe PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies. | ERC Starting... | € 1.141.779 | 2023 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian CellsINTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations. | ERC Advanced... | € 2.475.491 | 2023 | Details |
RNA-based gene writing in human cellsSCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications. | ERC Consolid... | € 1.999.465 | 2024 | Details |
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPRThis project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways. | ERC Starting... | € 1.499.923 | 2022 | Details |
Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells
INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.
RNA-based gene writing in human cells
SCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications.
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPR
This project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
FluEdit: Microfluidics Gen-editing platform voor bloedcellenNTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie. | Mkb-innovati... | € 20.000 | 2023 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
Next generation gene writing platform to cure genetic and oncological diseasesIntegra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases. | EIC Accelerator | € 2.496.375 | 2024 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
FluEdit: Microfluidics Gen-editing platform voor bloedcellen
NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
Next generation gene writing platform to cure genetic and oncological diseases
Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.